This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59%

Solid pharma stocks offer promising upside opportunities. This particular play is eyeing an entry as earnings surge.

Investors Business Daily • Mar 6, 2026

These Are The 5 Best Stocks To Buy Or Watch Now

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

Investors Business Daily • Mar 6, 2026

Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 2026 38 th  Annual ROTH Conference (Dana Point, Calif.

GlobeNewsWire • Mar 4, 2026

Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Robust financial performance driven by full year 2025 royalty revenue growth of  48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.

GlobeNewsWire • Feb 26, 2026

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

GlobeNewsWire • Feb 12, 2026

Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m.

GlobeNewsWire • Feb 4, 2026

This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth

With the tech sector coming under pressure many are looking for alternative investment areas. This pharma stock is an option worth considering.

Investors Business Daily • Jan 30, 2026

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Seeking Alpha • Dec 10, 2025

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002 Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound annual growth rate $1 billion in deployable capital expected to drive long-term royalty revenue growth JUPITER, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor Day in New York City today.

GlobeNewsWire • Dec 9, 2025